1657.1 – Rhenium-188 brachytherapy for non-melanoma skin cancer

New MBS item

The proposed service is a novel form of brachytherapy for non-melanoma skin cancer (NMSC), which uses the Beta emitter radioisotope Rhenium-188. During treatment, the affected area of the skin is covered with the sterile protective foil. The Rhenium-188 is then applied in a matrix on the foil using a special applicator device. The irradiation time required to achieve the desired target dose at the defined penetration depth is calculated based on the radioactivity of the substance being applied and the surface area to be treated. After the calculated irradiation time, the matrix is removed by pulling the foil from the skin. It can be provided without anaesthesia, over a short period of time in an outpatient setting.

Type: Therapeutic

NMSC, also known as keratinocyte cancer, includes basal cell carcinoma, squamous cell carcinoma, and various other less common lesions. The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Bypassing PASC
• Pre-MSAC consultation deadline: Friday 14 February 2025 11:59 pm AEDT

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: Bypassing PASC
• ESC meeting: 13 to 14 February 2025
• MSAC meeting: 3 to 4 April 2025

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.